Saeidreza JamaliMoghadamSiahkali1, Besharat Zarezade2, Sogol Koolaji3, SeyedAhmad SeyedAlinaghi4, Abolfazl Zendehdel5, Mohammad Tabarestani6, Ehsan Sekhavati Moghadam7, Ladan Abbasian2, Seyed Ali Dehghan Manshadi2, Mohamadreza Salehi2, Malihe Hasannezhad2, Sara Ghaderkhani2, Mohsen Meidani2, Faeze Salahshour8, Fatemeh Jafari2, Navid Manafi9, Fereshteh Ghiasvand10. 1. Department of Infectious Diseases, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran. 4. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. 5. Geriatric Department, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. 6. Students Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 7. Department of Cardiology, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. 8. Department of Radiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. 9. Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada. 10. Liver Transplantation Research Center, Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran. ghiasvand_62@yahoo.com.
Abstract
BACKGROUND:Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. RESULTS: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. CONCLUSIONS: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020.
RCT Entities:
BACKGROUND:Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. RESULTS: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. CONCLUSIONS: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020.
Entities:
Keywords:
2019-nCoV; COVID-19; Hydroxychloroquine; Lopinavir; Pneumonia; Ritonavir; SARS-COV-2; Vitamin C
Authors: Bernard J Fisher; Ignacio M Seropian; Donatas Kraskauskas; Jay N Thakkar; Norbert F Voelkel; Alpha A Fowler; Ramesh Natarajan Journal: Crit Care Med Date: 2011-06 Impact factor: 7.598
Authors: Sebastian J Padayatty; He Sun; Yaohui Wang; Hugh D Riordan; Stephen M Hewitt; Arie Katz; Robert A Wesley; Mark Levine Journal: Ann Intern Med Date: 2004-04-06 Impact factor: 25.391
Authors: Alpha A Fowler; Aamer A Syed; Shelley Knowlson; Robin Sculthorpe; Don Farthing; Christine DeWilde; Christine A Farthing; Terri L Larus; Erika Martin; Donald F Brophy; Seema Gupta; Bernard J Fisher; Ramesh Natarajan Journal: J Transl Med Date: 2014-01-31 Impact factor: 5.531
Authors: Sean S Scholz; Rainer Borgstedt; Nicole Ebeling; Leoni C Menzel; Gerrit Jansen; Sebastian Rehberg Journal: Crit Care Date: 2021-01-06 Impact factor: 9.097
Authors: Tadeo Bermudez; Saad Sammani; Jin H Song; Vivian Reyes Hernon; Carrie L Kempf; Alexander N Garcia; Jessica Burt; Matthew Hufford; Sara M Camp; Anne E Cress; Ankit A Desai; Viswanathan Natarajan; Jeffrey R Jacobson; Steven M Dudek; Leopoldo C Cancio; Julie Alvarez; Ruslan Rafikov; Yansong Li; Donna D Zhang; Nancy G Casanova; Christian Bime; Joe G N Garcia Journal: Sci Rep Date: 2022-01-13 Impact factor: 4.996
Authors: Vicente Javier Clemente-Suárez; Domingo Jesús Ramos-Campo; Juan Mielgo-Ayuso; Athanasios A Dalamitros; Pantelis A Nikolaidis; Alberto Hormeño-Holgado; Jose Francisco Tornero-Aguilera Journal: Nutrients Date: 2021-06-03 Impact factor: 5.717